Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03850418 · ClinicalTrials.gov registry record · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
A Phase 2 study of Myeloid Malignancy, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT03850418: Recruiting Phase 2 study of Myeloid Malignancy, sponsored by Henry Ford Health System.
NCT03850418 is a Phase 2 study of Myeloid Malignancy that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 43 participants, below the 347-participant average among 7 other Myeloid Malignancy trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03850418, a Phase 2 study of Myeloid Malignancy, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor chimerism and hence decrease relapse without increasing GVHD
Primary Outcome
To determine the rate of increase or stable donor chimerism when using low dose azacitidine post allogenic stem cell transplant (SCT) in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and myeloproliferative neoplasms (MPN) with documented low or decreasing donor chimerism
Conditions Studied
Interventions
- DRUG azacitidine
Study Locations (1)
Michigan
- Henry ford hospital - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2028-02-20 |
| Phase | Phase 2 |
What NCT03850418 shows while recruiting
NCT03850418 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 347-participant average among 7 other Myeloid Malignancy trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Myeloid Malignancy appearing as the primary indexed condition, and to 1 intervention - of which azacitidine is the first listed.
NCT03850418 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT03850418 about?
NCT03850418 is a clinical study titled "Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant". Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor chimerism and hence decrease relapse without increasing GVHD
What is the current status of trial NCT03850418?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2019-07-01. Estimated completion is 2028-02-20.
What conditions does trial NCT03850418 study?
This clinical trial studies the following conditions: Myeloid Malignancy.
What interventions are being tested in trial NCT03850418?
The interventions under investigation include: azacitidine (DRUG).
Who is sponsoring clinical trial NCT03850418?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03850418 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloid Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
RECRUITING · Phase 1
-
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
RECRUITING · Phase 1
-
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
RECRUITING · NA
-
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
RECRUITING · Phase 1
-
A Telehealth Advance Care Planning Intervention
RECRUITING · NA
-
Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
- NCT04305834 · 43 participants · Phase 2
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI